386 - Breast cancer patients with HER2neu overexpression: relationship among clinicopathological characteristics and local/distant recurrences and survival

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Biomarkers
Breast Cancer
Cancer Aetiology, Epidemiology, Prevention
Presenter Carla Bellido - Ribes
Authors C. Bellido - Ribes1, S. Gonzalez2, A. Garcia3, V. Obadia2, R. Bastus4, J. Fernández4, A. Aguilar4, L. Cirera4
  • 1Medical Oncology, Mutua terrassa University Hospital, 08221 - Terrassa/ES
  • 2Medical Oncology, Hospital Mutua Terrassa, 08221 - Terrassa/ES
  • 3Breast Unit, Departament Of Gynecology, Hospital mutua terrassa, 08221 - Terrassa/ES
  • 4Medical Oncologyst, Hospital Mutua Terrassa, 08221 - Terrassa/ES

Abstract

Objectives

The aim of this study was to correlate the overexpression of HER2 with clinical pathologic characteristics and its influence on local/distant recurrence and survival.

Methods

From 1998 to 2010, prospective data of 146 patients with invasive breast cancer with HER-2 overexpression was studied. The sample was divided into three groups: Negative hormonal receptors (NHR); Luminal B1 (Estrogen receptor +/-, Progesterone receptor +), Luminal B2 (Estrogen receptor +, Progesterone receptor -). Histological type (HT), size tumor (T), differentiation grade (DG), and nodal status were determined. Correlation with local and distant recurrence, and 5-year overall survival was done.

Results

NHR: 33.5%, luminal B1: 47.5%; Luminal B2: 19% Clinical pathologic characteristics:

Age (%) Size(%) HT (%)
<50 50-69 >70 T1 T2 T3 T4 Ductal Lobular
NHR 23 51 26 39 37 4 10 98 2
Luminal B1 33 51 16 51 39 9 1 99 1
Luminal B2 22 64 14 53 43 30 4 96 4

DG (%) Nodal Status
G1 G2 G3 Negative Positive
NHR 0 21 79 59 41
Luminal B1 11 37 52 48 52
Luminal B 0 28 73 57 43

Local and distant recurrence and overall survival at 5 years follow-up:

Local Recurrence(%) Metastasis Recurrence(%) Overall Survival (%)
NHR 6 20 81.5
Luminal B1 2 8 88.5
Luminal B2 4 15 86.5

Conclusions

Patients with NHR and patients with PR- had more aggressive differentiation grade, less axillary infiltration and increased risk of distant metastasis. At 5-year follow-up, overall survival was better in the PR+ group.

Disclosure

All authors have declared no conflicts of interest.